The use of multicolor fluorescence technologies in the characterization of prostate carcinoma cell lines: A comparison of multiplex fluorescence in situ hybridization and spectral karyotyping data

Cancer Genetics and Cytogenetics

Volumn 124, Issue 2, 2001, Pages 112-121

  Strefford, Jon C ^a   Lillington, Debra M ^a   Young, Bryan D ^a   Oliver, R T D ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHROMOSOME 1; CHROMOSOME 10; CHROMOSOME 8; CHROMOSOME ABERRATION; CHROMOSOME PAINTING; CHROMOSOME TRANSLOCATION; FLUORESCENCE; FLUORESCENCE IN SITU HYBRIDIZATION; HORMONE RESISTANCE; INTERMETHOD COMPARISON; KARYOTYPING; PRIORITY JOURNAL; PROSTATE CARCINOMA;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; CARCINOMA; CHROMOSOME BANDING; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; MALE; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0035863261     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(00)00339-3     Document Type: Article

References (59)

1. The epidemolgy of prostate cancer. Geographical distribution and time-trends
2. Chemotherapy for advanced hormone refractory prostate cancer
3. Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer
4. Tumor suppressosr gene p53 mutations in human prostate cancer
5. Retinoblastoma gene mutations in primary human prostate cancer
6. Frequent loss of expression and loss of heterozygosity of the putative tumor suppressor gene DCC in prostatic carcinomas
7. ras gene mutations in human prostate cancer
8. Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers
9. Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization
10. Evaluation of 20 archival prostate tumor specimens by fluorescence in situ hybridization (FISH)
11. Assessment of chromosomal trisomies in prostate cancer using fluorescent in situ hybridization
12. Chromosome 16 allelic loss analysis of a large set of microdissected prostate carcinomas
13. Loss of heterozygosity on chromosome 13 is associated with advanced stage prostate cancer
14. Loss of heterozygosity at chromosome arm 13q and RB1 status in human prostate cancer
15. Distinct deleted regions on chromosome segment 16q23-24 associated with metastases in prostate cancer
16. Identification of a I-cM region of common deletion on 13q14 associated with human prostate cancer
17. The LNCaP cell line-a new model for studies on human prostatic carcinoma
18. Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP
19. Isolation of a human prostate carcinoma cell line (DU 145)
20. Establishment and characterization of a human prostatic carcinoma cell line (PC-3)
21. Karyotyping human chromosomes by combinatorial multi-fluor FISH
22. Multiplex fluorescence in situ hybridisation and cross species colour banding of a case of chronic myeloid leukemia in blast crisis with a complex Philadelphia translocation
23. Characterisation of the human myeloid leukemia-derived cell line GF-D8 by multiplex fluorescence in situ hybridisation, subtelomeric probes, and comparative genomic hybridisation
24. Hidden chromosome abnormalities in haematological malignancies detected by multicolour spectral karyotyping
25. Analysis of B-cell neoplasias by spectral karyotyping (SKY)
26. Increased karyotype precision using fluorescence in situ hybridization and spectral karyotyping in patients with myeloid malignancies
27. Spectral karyotyping and chromosome banding studies of primary breast carcinomas and their lymph node metastases
28. Molecular cytogenetic analysis of the bladder carcinoma cell line BK-10 by spectral karyotyping
29. Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping
30. Identification of a high frequency of chromosomal rearrangements in the centromeric regions of prostate cancer cell lines by spectral karyotyping
31. Chromosome banding techniques
32. A high-resolution study of chromosome changes in a human prostatic carcinoma cell line (LNCaP)
33. LNCaP model of human prostatic carcinoma
34. The t(6;16)(p21;q22) chromosome translocation in the LNCaP prostate carcinoma cell line results in a tpc/hpr fusion gene
35. Characterization of chromosome 8 aberrations in the prostate cancer cell line LNCaP-FGC and sublines
36. Rearrangement of the long arm of chromosome 10 in the prostate adenocarcinoma cell line LNCaP
37. Structural alterations of chromosome 5 in twelve human prostate cancer cell lines
38. Cytogenetic survey of 32 cancers of the prostate
39. Loss of the chromosomal region 10q23-25 in prostate cancer
40. Allelic loss on chromosome 10 in prostate adenocarcinoma
41. Microsatellite instability and deletion analysis of chromosome 10 in human prostate cancer
42. Distinct areas of allelic loss on chromosomal regions 10p and 10q in human prostate cancer
43. Is chromosome 10 a primary chromosomal abnormality in endometrial adenocarcinoma?
44. Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10
45. Deletion mapping of the long arm of chromosome 10 in glioblastoma multiforme
46. Loss of heterozygosity for 10q loci in human gliomas
47. Possible involvement of the chromosome region 10q24-q26 in early stages of melanocytic neoplasia
48. Loss of heterozygosity for 10q22-10qter in malignant melanoma progression
49. Recurrent abnormalities of chromosome bands 10q23-25 in non-Hodgkin's lymphoma
50. Common regions of deletion on chromosomes 5q, 6q, and 10q in renal cell carcinoma
51. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and alleotyping
52. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization
53. Aneusomies of chromosomes 8 and Y detected by fluorescence in situ hybridization are prognostic markers for pathological stage C (pt3N0M0) prostate carcinoma
54. Mapping of chromosomal gains and losses in prostate cancer by comparative genomic hybridization
55. Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer
56. Chromosomal analysis of human prostatic adenocarcinoma cell lines